TODAY: Gb Sciences showcases its PhAROS™ drug discovery platform at the 2nd ALCOR Drug Discovery Platform Summit
President and Scientific Director Dr. Andrea Small-Howard demonstrates the utility of the platform in predicting novel plant-inspired drug candidates and describes its role in Gb Sciences’ future successes
May 12, 2022
LAS VEGAS, May 12, 2022 (Newswire.com) –
Dr. Andrea Small-Howard, President and Scientific Director of GB Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, today discusses the current and future importance of its proprietary drug discovery platform PhAROS™ (Phytomedical Analysis for Research Optimization scale) at the 2nd ALCOR Drug Discovery Platform Summit.
“Demonstrating the capabilities of our new drug discovery platform at ALCOR’s 2nd Drug Discovery Platform Summit provides us with the opportunity to engage with scientists, researchers and decision makers representing more than 120 companies around the world“, says Dr. Small-Howard. Please visit the following site link for more information about the conference.
PhAROS™ uses AI-enhanced data analytics and machine learning to identify and predict the effectiveness of combinations of novel plant-derived active ingredients (aka “minimum essential blends”). Gb Sciences’ proprietary minimum essential blends are designed to retain the efficacy of whole herbal therapies while maintaining the manufacturing and quality control advantages of single ingredient pharmaceuticals.
To date, PhAROS™ has identified potential plant-inspired therapeutic blends for the treatment of neurological disorders, inflammation, anxiety, depression, heart disease, metabolic syndrome, chronic pain and more. . These minimum essential mixtures were then validated in cellular and now animal models for safety and efficacy testing in human clinical trials. Recently, Gb Sciences was granted four US patents for its late-stage preclinical formulations which are being developed for the treatment of Parkinson’s disease, inflammation, chronic pain and heart disease, respectively. As Gb Sciences’ drug development pipeline advances these drug candidates into human clinical trials, the value of the PhAROS™ drug discovery platform increases, becoming an important asset for the future growth of the company. society.
For more information on Gb Sciences, please visit https://gbsciences.com/.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a company inspired by plants, biopharmaceutical research and a development company creating proprietary formulations of cannabis and other plant-inspired therapeutic blends for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant-inspired” active ingredients in its therapeutic blends are synthetic counterparts identical to the original plant compounds but produced under current good manufacturing practices. Gb Sciences’ intellectual property portfolio contains six issued US patents and three issued foreign patents, as well as 18 US patents and 49 foreign patents pending. In its drug development pipeline, Gb Sciences has five preclinical-stage product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-man clinical trial. Gb Sciences formulations for chronic pain, anxiety and depression are currently undergoing preclinical animal studies with researchers at the National Research Council of Canada. The company also recently received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of COVID-19-related cytokine release syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes renowned universities, hospitals and contract research organizations. To learn more, visit www.gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as ‘expects’, ‘intends’, ‘plans’, ‘may’, ‘could’, ‘should’, ‘anticipates’, ‘probably’, ‘believes’ and words of of similar significance may identify forward-looking statements. These statements are not historical facts but rather represent the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and beyond the Company’s control. It is possible that the actual results and financial condition of the Company will differ, perhaps materially, from the anticipated results and financial condition indicated in these forward-looking statements. In addition, information regarding the Company and its business, including factors that could materially affect the Company’s financial and other business and results, can be found in the Company’s filings with the Securities and Exchange Commission, available at at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that occur subsequently or of which we become aware subsequently.
Source: GB Sciences